| Literature DB >> 23885662 |
Vikram M Velker1, George B Rodrigues, Robert Dinniwell, Jeremiah Hwee, Alexander V Louie.
Abstract
BACKGROUND: Increasing use of IMRT to treat breast and prostate cancers at high risk of regional nodal spread relies on accurate contouring of targets and organs at risk, which is subject to significant inter- and intra-observer variability. This study sought to evaluate the performance of an atlas based deformable registration algorithm to create multi-patient CT based atlases for automated contouring.Entities:
Mesh:
Year: 2013 PMID: 23885662 PMCID: PMC3726483 DOI: 10.1186/1748-717X-8-188
Source DB: PubMed Journal: Radiat Oncol ISSN: 1748-717X Impact factor: 3.481
Figure 1Atlas building process map.
DSC comparison of atlas predicted ROIs to manually contoured gold standard for the locoregional breast cancer atlases
| Breast and Chest wall | CTVBRCWL | 0.87 | (0.03, 0.80–0.92) | 0.89 | (0.04, 0.79–0.94) |
| Axilla I | CTVAX1 | 0.72 | (0.09, 0.43–0.86) | 0.75 | (0.08, 0.59–0.87) |
| Axilla II | CTVAX2 | 0.74 | (0.06, 0.62–0.87) | 0.73 | (0.06, 0.63–0.84) |
| Axilla III | CTVAX3 | 0.69 | (0.08, 0.52–0.80) | 0.73 | (0.07, 0.54–0.83) |
| Supraclavicular | CTVSCV | 0.72 | (0.07, 0.57–0.82) | 0.70 | (0.08, 0.52–0.82) |
| Intramammary Nodes | CTVIMN | 0.25 | (0.14, 0.01–0.59) | 0.33 | (0.15, 0.03–0.58) |
| Lumpectomy Cavity | LUMP | 0.10 | (0.20, 0–0.69) | 0.04 | (0.11, 0–0.89) |
| Heart | H | 0.89 | (0.03, 0.81–0.92) | 0.90 | (0.04, 0.81–0.95) |
| Left Lung | LL | 0.97 | (0.01, 0.96–0.98) | 0.97 | (0.01, 0.95–0.98) |
| Right Lung | RL | 0.97 | (0.01, 0.95–0.99) | 0.97 | (0.01, 0.96–0.98) |
N = 25 Left-, 25 Right- High Risk Post Lumpectomy Cases.
Figure 2Atlas-predicted contouring for high risk breast cancer post lumpectomy. Representative slices of two contoured right breast-post lumpectomy cases comparing atlas predicted auto contours (bold outline) to manual contoured standard (thin outline with colourwash). Atlas subjects #5 (left images) and #14 (right images). ROIs demonstrated are CTVBRCWL (purple), CTVAX1 (yellow), CTVAX2 (pink), CTVAX3 (dark blue), CTVSCV (teal), LUMP (orange), H (red), LL(light yellow), RL(green). Bottom panels demonstrate the high degree of variability in seroma (LUMP) prediction with the atlas being unable to predict the subtle seroma (left images, DSC = 0) while contouring a more readily identifiable seroma with reasonable accuracy (right images, DSC = 0.89).
DSC comparison of atlas predicted ROIs to manually contoured gold standard for high risk prostate cancer atlas
| Prostate | CTVPROS | 0.71 | (0.12, 0.35–0.84) |
| Pelvic Nodes | CTVNODES | 0.71 | (0.07, 0.58–0.79) |
| Bladder | B | 0.83 | (0.10, 0.63–0.95) |
| Rectum | R | 0.48 | (0.19, 0.17–0.76) |
| Seminal Vesicles | SV | 0.30 | (0.31, 0–0.79) |
| Penile Bulb | PB | 0.39 | (0.22, 0–0.67) |
| Left Femoral Head | LF | 0.89 | (0.09, 0.63–0.95) |
| Right Femoral Head | RF | 0.93 | (0.03, 0.86–0.96) |
N = 14 High Risk Prostate Cancer Cases.
Figure 3Atlas-predicted contouring for high risk prostate cancer. Sample slices of contoured high risk prostate cases comparing atlas predicted auto contours (bold outline) to manual contoured standard (thin outline with colourwash). ROIs demonstrated are CTVPROS (purple), CTVNODES (red), B (Green), R (Orange), PB (dark purple), SV (cyan), LF and RF (dark blue).